Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Genocea Biosciences

DB:GBI1
Snowflake Description

Fair value with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GBI1
DB
$46M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Genocea Biosciences has significant price volatility in the past 3 months.
GBI1 Share Price and Events
7 Day Returns
-3.3%
DB:GBI1
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-68.3%
DB:GBI1
-13.2%
DE Biotechs
-20.9%
DE Market
GBI1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genocea Biosciences (GBI1) -3.3% -16.4% -26.7% -68.3% -96.7% -98.5%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • GBI1 underperformed the Biotechs industry which returned -13.2% over the past year.
  • GBI1 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
GBI1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Genocea Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Genocea Biosciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Genocea Biosciences.

DB:GBI1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GBI1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (43.41%))
1.399
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.4
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.399 * 5.44%)
7.22%

Discounted Cash Flow Calculation for DB:GBI1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Genocea Biosciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:GBI1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.22%)
2020 -46.00 Analyst x1 -42.90
2021 -59.00 Analyst x1 -51.32
2022 -71.00 Analyst x1 -57.60
2023 -56.00 Analyst x1 -42.37
2024 25.00 Analyst x1 17.64
2025 29.17 Est @ 16.67% 19.20
2026 32.54 Est @ 11.55% 19.97
2027 35.13 Est @ 7.97% 20.11
2028 37.05 Est @ 5.46% 19.78
2029 38.42 Est @ 3.71% 19.14
Present value of next 10 years cash flows $-78.00
DB:GBI1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $38.42 × (1 + -0.39%) ÷ (7.22% – -0.39%)
$502.98
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $502.98 ÷ (1 + 7.22%)10
$250.50
DB:GBI1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-78.00 + $250.50
$172.50
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $172.50 / 27.64
$6.24
DB:GBI1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GBI1 represents 0.89157x of NasdaqCM:GNCA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89157x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 6.24 x 0.89157
€5.56
Value per share (EUR) From above. €5.56
Current discount Discount to share price of €1.48
= -1 x (€1.48 - €5.56) / €5.56
73.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Genocea Biosciences is available for.
Intrinsic value
>50%
Share price is €1.48 vs Future cash flow value of €5.56
Current Discount Checks
For Genocea Biosciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Genocea Biosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Genocea Biosciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genocea Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genocea Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GBI1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.89
NasdaqCM:GNCA Share Price ** NasdaqCM (2020-04-03) in USD $1.66
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genocea Biosciences.

DB:GBI1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:GNCA Share Price ÷ EPS (both in USD)

= 1.66 ÷ -1.89

-0.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genocea Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Genocea Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Genocea Biosciences's expected growth come at a high price?
Raw Data
DB:GBI1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-10.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genocea Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genocea Biosciences's assets?
Raw Data
DB:GBI1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.89
NasdaqCM:GNCA Share Price * NasdaqCM (2020-04-03) in USD $1.66
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:GBI1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:GNCA Share Price ÷ Book Value per Share (both in USD)

= 1.66 ÷ 0.89

1.87x

* Primary Listing of Genocea Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genocea Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Genocea Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genocea Biosciences has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Genocea Biosciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-10.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genocea Biosciences expected to grow at an attractive rate?
  • Unable to compare Genocea Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Genocea Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Genocea Biosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:GBI1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GBI1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -10.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GBI1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GBI1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 0 50 -67 1
2023-12-31 0 -36 -44 1
2022-12-31 0 -57 -61 4
2021-12-31 0 -49 -49 5
2020-12-31 0 -41 -43 5
2020-04-06
DB:GBI1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -38 -39
2019-09-30 -37 -29
2019-06-30 -36 -30
2019-03-31 -38 -27
2018-12-31 -41 -28
2018-09-30 -41 -39
2018-06-30 -43 -48
2018-03-31 -46 -59
2017-12-31 -48 -57
2017-09-30 0 -51 -62
2017-06-30 0 -50 -58
2017-03-31 0 -46 -54

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genocea Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Genocea Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GBI1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Genocea Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GBI1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.98 -0.98 -0.98 1.00
2023-12-31 -0.68 -0.68 -0.68 1.00
2022-12-31 -1.39 -0.59 -2.36 4.00
2021-12-31 -1.33 -0.78 -2.29 5.00
2020-12-31 -1.36 -1.10 -1.68 5.00
2020-04-06
DB:GBI1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.89
2019-09-30 -1.78
2019-06-30 -2.38
2019-03-31 -2.44
2018-12-31 -2.69
2018-09-30 -4.57
2018-06-30 -7.16
2018-03-31 -11.99
2017-12-31 -15.86
2017-09-30 -17.39
2017-06-30 -16.28
2017-03-31 -15.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genocea Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Genocea Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genocea Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Genocea Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genocea Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genocea Biosciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Genocea Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genocea Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Genocea Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genocea Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GBI1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -38.95 12.04
2019-09-30 -29.24 11.62 25.21
2019-06-30 -29.55 12.96 25.88
2019-03-31 -27.49 14.22 25.21
2018-12-31 -27.81 14.31
2018-09-30 -38.89 14.16 39.20
2018-06-30 -47.93 13.81 51.50
2018-03-31 -58.87 12.91 39.20
2017-12-31 -56.71 13.43 39.20
2017-09-30 0.00 -62.01 14.81
2017-06-30 0.00 -57.91 14.68
2017-03-31 0.00 -53.56 15.14
2016-12-31 0.24 -49.57 15.43
2016-09-30 0.46 -43.85 15.35
2016-06-30 0.67 -40.86 15.38
2016-03-31 0.78 -40.15 14.52
2015-12-31 0.67 -42.48 13.99
2015-09-30 0.76 -43.82 12.79
2015-06-30 0.54 -43.22 11.98
2015-03-31 0.43 -40.05 11.17
2014-12-31 0.31 -35.48 9.75
2014-09-30 0.02 -30.58 9.02
2014-06-30 0.24 -26.65 7.60
2014-03-31 0.47 -24.86 6.12
2013-12-31 0.73 -22.41 4.96
2013-09-30 1.25 -20.90 4.19
2013-06-30 1.42 -19.79 3.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genocea Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genocea Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genocea Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genocea Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genocea Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Genocea Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genocea Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genocea Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genocea Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genocea Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genocea Biosciences Company Filings, last reported 3 months ago.

DB:GBI1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 25.04 13.41 40.13
2019-09-30 31.37 13.30 46.65
2019-06-30 38.44 13.73 58.67
2019-03-31 6.24 14.12 29.04
2018-12-31 7.34 14.82 26.36
2018-09-30 6.50 14.64 34.49
2018-06-30 13.87 14.47 44.22
2018-03-31 14.57 13.87 51.18
2017-12-31 -6.05 14.31 12.27
2017-09-30 3.69 15.78 21.98
2017-06-30 19.21 17.21 35.23
2017-03-31 33.08 17.08 48.68
2016-12-31 45.54 16.96 63.36
2016-09-30 60.35 16.83 75.46
2016-06-30 71.87 16.71 85.97
2016-03-31 80.99 16.59 95.66
2015-12-31 89.66 16.48 94.33
2015-09-30 98.89 11.66 97.61
2015-06-30 60.66 11.56 74.60
2015-03-31 69.75 11.58 84.49
2014-12-31 32.51 11.39 47.08
2014-09-30 40.96 9.63 52.19
2014-06-30 49.04 9.83 59.18
2014-03-31 55.37 9.81 65.84
2013-12-31 2.09 9.79 12.21
2013-09-30 8.14 3.28 12.08
2013-06-30 12.51 3.21 16.07
  • Genocea Biosciences's level of debt (53.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (34.6% vs 53.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Genocea Biosciences has less than a year of cash runway based on current free cash flow.
  • Genocea Biosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.7% each year.
X
Financial health checks
We assess Genocea Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genocea Biosciences has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Genocea Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genocea Biosciences dividends.
If you bought €2,000 of Genocea Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genocea Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genocea Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GBI1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GBI1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genocea Biosciences has not reported any payouts.
  • Unable to verify if Genocea Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genocea Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genocea Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genocea Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genocea Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genocea Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Genocea Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chip Clark
COMPENSATION $1,311,026
AGE 50
TENURE AS CEO 9.2 years
CEO Bio

Mr. William D. Clark, also known as Chip, M.B.A. has been the Chief Executive Officer and President at Genocea Biosciences, Inc. since February 2011. Mr. Clark served as Chief Financial Officer of Cubist Pharmaceuticals, Inc. Mr. Clark served as the Chief Business Officer at Genocea Biosciences, Inc. from August 2010 to February 2011. Mr. Clark served as the Chief Business Officer, Senior Vice President and Secretary of Vanda Pharmaceuticals, Inc. from September 2004 to March 26, 2010, which he co-founded in 2004. While at Vanda, he led the company's strategic and business development activities and played a central role in raising more than $220 million in multiple public and private financings. Mr. Clark has more than 20 years of biotechnology and pharmaceutical experience with a focus on commercialization, business development and venture capital financing. Prior to Vanda, Mr. Clark was a Principal of Care Capital LLC, Care Capital Investments II, L.P. and Care Capital Investments III, L.P. Prior to joining Care Capital, he served as an Associate Director of Business Development for SmithKline Beecham Seiyaku (now GlaxoSmithKline), the Japanese affiliate of SB. There, he led the effort to establish a health care information business in Japan. He also evaluated the scientific and commercial prospects and developed the marketing plans for drug candidates. He worked at GlaxoSmithKline plc in a variety of commercial and strategic roles. Before Japan, he worked for SB in London, evaluating corporate strategic initiatives and helping to direct senior management's long-range planning efforts. He has been a Director of Arsanis, Inc. since September 2017. He has been a Director of Genocea Biosciences, Inc. since February 2011. He served as a Director of Vanda Pharmaceuticals, Inc. from 2003 to 2004. He has experience as a founder and senior executive officer of other biopharmaceutical companies, as well as has prior public company board service. Mr. Clark received a B.A. from Harvard University and an MBA from The Wharton School, University of Pennsylvania.

CEO Compensation
  • Chip's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chip's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Genocea Biosciences management team in years:

1.8
Average Tenure
47
Average Age
  • The average tenure for the Genocea Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Chip Clark

TITLE
President
COMPENSATION
$1M
AGE
50
TENURE
9.2 yrs

Jessica Flechtner

TITLE
Chief Scientific Officer
COMPENSATION
$734K
AGE
47
TENURE
4.2 yrs

Diantha Duvall

TITLE
Chief Financial Officer
AGE
47
TENURE
1.1 yrs

Narinderjeet Singh

TITLE
Senior VP of Pharmaceutical Sciences & Manufacturing
AGE
47
TENURE
2.1 yrs

Tom Davis

TITLE
Chief Medical Officer
AGE
55
TENURE
1.5 yrs

Girish Aakalu

TITLE
Chief Business Officer
AGE
44
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Genocea Biosciences board of directors in years:

3.8
Average Tenure
56
Average Age
  • The tenure for the Genocea Biosciences board of directors is about average.
Board of Directors

Ken Bate

TITLE
Chairman of the Board
COMPENSATION
$100K
AGE
69
TENURE
1.3 yrs

Chip Clark

TITLE
President
COMPENSATION
$1M
AGE
50
TENURE
9.2 yrs

George Siber

TITLE
Chairman of Scientific Advisory Board & Director
COMPENSATION
$207K
AGE
74

Katrine Bosley

TITLE
Independent Director
COMPENSATION
$125K
AGE
51
TENURE
7.1 yrs

Michael Higgins

TITLE
Independent Director
COMPENSATION
$95K
AGE
57
TENURE
5.2 yrs

Ron Cooper

TITLE
Independent Director
COMPENSATION
$91K
AGE
56
TENURE
3.8 yrs

Howard Mayer

TITLE
Independent Director
COMPENSATION
$85K
AGE
56
TENURE
3.1 yrs

Ali Behbahani

TITLE
Independent Director
COMPENSATION
$106K
AGE
43
TENURE
2.2 yrs

Chuck Drake

TITLE
Member of Scientific Advisory Board

Eric Tran

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Jun 19 Buy GlaxoSmithKline plc Company 24. Jun 19 24. Jun 19 1,857,142 €3.07 €5,701,797
25. Jun 19 Buy New Enterprise Associates, Inc. Company 24. Jun 19 24. Jun 19 2,857,142 €3.07 €8,771,997
X
Management checks
We assess Genocea Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genocea Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Details
Name: Genocea Biosciences, Inc.
GBI1
Exchange: DB
Founded: 2006
$42,534,202
27,643,773
Website: http://www.genocea.com
Address: Genocea Biosciences, Inc.
100 Acorn Park Drive,
5th Floor,
Cambridge,
Massachusetts, 02140,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM GNCA Common Stock Nasdaq Capital Market US USD 05. Feb 2014
DB GBI1 Common Stock Deutsche Boerse AG DE EUR 05. Feb 2014
Number of employees
Current staff
Staff numbers
59
Genocea Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 02:49
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.